Uncertain indications are those with either published evidence or lack of expert consensus on testing use. AUCs also include relevant clinical scenarios not ad- dressed by these guidelines,11 such as the issue of testing during follow-up of patients with SIHD with stress echocar- diography,15 single-photon emission computed tomography (SPECT) MPI,12 CMR, and CCTA.13,14 These AUC docu- ments address the intervals between testing for various stress imaging indications. As with all standards documents, ongo- ing evaluation is required to update the recommendations on the value, limitations, timing, costs, and risks of imaging as an adjunct to clinical assessment during follow-up of patients with established SIHD. Review of these AUCs is beyond the scope of the present document, and the reader is referred to the most recent AUC documents to complement the guide- lines provided here. As the scientific basis of the approach to management of cardiovascular disease has rapidly expanded, the size and scope of clinical practice guidelines have grown commensu- rately to a point where they have become too unwieldy for routine use by practicing clinicians. The most current national guidelines for management of hypertension (Joint National Committee VII)17 and hyperlipidemia (Adult Treatment Panel III)18 combined comprise nearly 400 pages. Thus, the writing committee recognized that it would be unfeasible to produce a document that would be simultaneously practical and exhaustive and, therefore, has tried to create a resource that provides a comprehensive approach to management of SIHD for which the relevant evidence is succinctly summarized and referenced. The writing committee used current and credible meta-analyses, when available, instead of conducting a sys- tematic review of all primary literature. 1.6. Magnitude of the Problem IHD remains a major public health problem nationally and internationally. 